Drug Trial Radar · NCT07573631
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
18
Planned (sponsor's estimate)
Start
Apr 20, 2026
Primary completion
Dec 2031
Study completion Dec 2031
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- May 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label extension study aims to evaluate the long-term safety and tolerability of weekly BMN 351 infusions, as well as to assess the effect of BMN 351 on physical function, in participants with DMD who participated in the 351-201 study.
Conditions
- Duchenne Muscular Dystrophy (DMD)
Interventions
BMN 351Drug
Anti-sense Oligonucleotide BMN 351 will be administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the long-term safety and tolerability of BMN 351 in participants with DMDTime frame: Through study completion, at least 1 year
Locations
6 sites in 5 countries. Site status is shown where the registry gives one.
Fondazione Serena ETS - Centro Clinico NeMO Milano
Milan, Italy, Italy
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, Italy, Italy
Leids Universitair Medisch Centrum
Leiden, Netherlands, Netherlands
Hospital Viamed Santa Angela De la Cruz
Seville, Spain, Spain
Yeditepe University Kosuyolu Hospital
Istanbul, Turkey, Turkey (Türkiye)
Great Ormond Street Hospital NHS Foundation Trust
London, United Kingdom, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.